Medicina generalis - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 62,385 | 63,389 | 18,760 | 44,327 | 105,079 | 65,820 | 49,005 | 33,081 |
| Profit before tax | 7,592 | 12,718 | -2,381 | 13,465 | 26,571 | 4,641 | 5,868 | -4,102 |
| Net profit | 7,121 | 12,077 | -2,381 | 12,990 | 25,216 | 4,082 | 5,532 | -4,102 |
| Equity | 4,199 | 4,199 | 1,818 | 4,199 | 4,199 | 8,281 | 13,813 | 9,711 |
| Liabilities | 9,546 | 14,728 | 0 | 12,169 | 27,709 | 1,259 | 1,000 | 939 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 13,745 | 18,927 | 1,818 | 16,368 | 31,908 | 9,540 | 14,813 | 10,650 |
| Total assets | 13,745 | 18,927 | 1,818 | 16,368 | 31,908 | 9,540 | 14,813 | 10,650 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 8,004 | 2,065 | 2,011 |
| Social insurance contributions | - | - | - | - | - | 5,960 | 4,696 | 4,422 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -0.1% | +1.6% | -70.4% | +136.3% | +137.1% | -37.4% | -25.5% | -32.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 51.8% | 63.8% | -131.0% | 79.4% | 79.0% | 42.8% | 37.3% | -38.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 169.6% | 287.6% | -131.0% | 309.4% | 600.5% | 49.3% | 40.0% | -42.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 11.4% | 19.1% | -12.7% | 29.3% | 24.0% | 6.2% | 11.3% | -12.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 12.2% | 20.1% | -12.7% | 30.4% | 25.3% | 7.1% | 12.0% | -12.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.3 | 3.5 | - | 2.9 | 6.6 | 0.2 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 10,398 | 10,565 | 3,463 | 7,188 | 20,338 | 13,164 | 9,801 | 6,616 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Medicina generalis - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-11-21 | 2022-11-28 | 0.01 |
| 2022-11-17 | 2022-11-18 | 0.01 |
| 2022-09-16 | 2022-09-27 | 1.68 |
| 2022-07-18 | 2022-07-27 | 0.18 |
| 2022-06-16 | 2022-06-28 | 0.09 |
| 2022-05-17 | 2022-05-29 | 0.09 |
| 2022-04-28 | 2022-04-28 | 0.09 |
| 2022-02-17 | 2022-02-23 | 31.97 |
Medicina generalis - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Medicina generalis, UAB (Private Limited Liability Company), company code 125239176, operates in other human health activities n.e.c. In 2025, revenue declined to €33.1K from €49.0K in 2024 and €65.8K in 2023, representing a two-year drop of 49.7%. The company moved from profitability to a loss: net profit was €4.1K in 2023, rose to €5.5K in 2024, and fell to a net loss of €4.1K in 2025. Profit margin followed the same pattern, improving to 11.3% in 2024 before turning to -12.4% in 2025. At the end of 2025, total assets were €10.7K, down from €14.8K a year earlier, while equity decreased to €9.7K. Liabilities remained low at €939, and the equity ratio stayed high at 91.2%, with debt-to-equity at 0.10. Asset turnover was 3.11x. Return on equity was -42.2% and return on assets -38.5%, reflecting the loss-making year. Revenue per employee was €6.6K, and profit per employee was -€820.